Different  ||| S:0 E:10 ||| JJ
sensitivity  ||| S:10 E:22 ||| NN
levels  ||| S:22 E:29 ||| NNS
to  ||| S:29 E:32 ||| TO
norspermidine  ||| S:32 E:46 ||| VB
on  ||| S:46 E:49 ||| IN
biofilm  ||| S:49 E:57 ||| JJ
formation  ||| S:57 E:67 ||| NN
in  ||| S:67 E:70 ||| IN
clinical  ||| S:70 E:79 ||| JJ
and  ||| S:79 E:83 ||| CC
commensal  ||| S:83 E:93 ||| FW
Staphylococcus  ||| S:93 E:108 ||| FW
epidermidis  ||| S:108 E:120 ||| FW
strains  ||| S:120 E:128 ||| FW
Biofilm  ||| S:128 E:136 ||| FW
formation  ||| S:136 E:146 ||| NN
on  ||| S:146 E:149 ||| IN
medical  ||| S:149 E:157 ||| JJ
and  ||| S:157 E:161 ||| CC
surgical  ||| S:161 E:170 ||| JJ
devices  ||| S:170 E:178 ||| NNS
is  ||| S:178 E:181 ||| VBZ
the  ||| S:181 E:185 ||| DT
main  ||| S:185 E:190 ||| JJ
virulence  ||| S:190 E:200 ||| NN
factor  ||| S:200 E:207 ||| NN
of  ||| S:207 E:210 ||| IN
Staphylococcus  ||| S:210 E:225 ||| NNP
epidermidis ||| S:225 E:236 ||| NN
.  ||| S:236 E:238 ||| .
A  ||| S:238 E:240 ||| DT
recent  ||| S:240 E:247 ||| JJ
study  ||| S:247 E:253 ||| NN
has  ||| S:253 E:257 ||| VBZ
shown  ||| S:257 E:263 ||| VBN
that  ||| S:263 E:268 ||| IN
norspermidine  ||| S:268 E:282 ||| JJ
inhibits  ||| S:282 E:291 ||| NN
and  ||| S:291 E:295 ||| CC
disassembles  ||| S:295 E:308 ||| VBG
the  ||| S:308 E:312 ||| DT
biofilm  ||| S:312 E:320 ||| NN
in  ||| S:320 E:323 ||| IN
the  ||| S:323 E:327 ||| DT
wild-type  ||| S:327 E:337 ||| JJ
Bacillus  ||| S:337 E:346 ||| NN
subtilis  ||| S:346 E:355 ||| VBD
NCBI3610  ||| S:355 E:364 ||| CD
strain ||| S:364 E:370 ||| NN
.  ||| S:370 E:372 ||| .
In  ||| S:372 E:375 ||| IN
this  ||| S:375 E:380 ||| DT
study ||| S:380 E:385 ||| NN
,  ||| S:385 E:387 ||| ,
the  ||| S:387 E:391 ||| DT
effect  ||| S:391 E:398 ||| NN
of  ||| S:398 E:401 ||| IN
norspermidine  ||| S:401 E:415 ||| NN
on  ||| S:415 E:418 ||| IN
S. epidermidis  ||| S:418 E:433 ||| CD
biofilm  ||| S:433 E:441 ||| JJ
formation  ||| S:441 E:451 ||| NN
of  ||| S:451 E:454 ||| IN
clinical  ||| S:454 E:463 ||| JJ
or  ||| S:463 E:466 ||| CC
commensal  ||| S:466 E:476 ||| JJ
strains  ||| S:476 E:484 ||| NNS
was  ||| S:484 E:488 ||| VBD
tested ||| S:488 E:494 ||| VBN
.  ||| S:494 E:496 ||| .
Biofilm  ||| S:496 E:504 ||| RB
producing  ||| S:504 E:514 ||| VBG
strains  ||| S:514 E:522 ||| NNS
of  ||| S:522 E:525 ||| IN
S. epidermidis  ||| S:525 E:540 ||| NNP
were  ||| S:540 E:545 ||| VBD
isolated  ||| S:545 E:554 ||| VBN
from  ||| S:554 E:559 ||| IN
healthy  ||| S:559 E:567 ||| JJ
skin  ||| S:567 E:572 ||| NN
( ||| S:572 E:573 ||| -LRB-
HS ||| S:573 E:575 ||| NNP
;  ||| S:575 E:577 ||| :
n = 3 ||| S:577 E:582 ||| CD
) ||| S:582 E:583 ||| -RRB-
,  ||| S:583 E:585 ||| ,
healthy  ||| S:585 E:593 ||| JJ
conjunctiva  ||| S:593 E:605 ||| NNS
( ||| S:605 E:606 ||| -LRB-
HC ||| S:606 E:608 ||| NNP
;  ||| S:608 E:610 ||| :
n = 9 ||| S:610 E:615 ||| CD
)  ||| S:615 E:617 ||| -RRB-
and  ||| S:617 E:621 ||| CC
ocular  ||| S:621 E:628 ||| JJ
infection  ||| S:628 E:638 ||| NN
( ||| S:638 E:639 ||| -LRB-
OI ||| S:639 E:641 ||| NNP
;  ||| S:641 E:643 ||| :
n = 19 ||| S:643 E:649 ||| CD
) ||| S:649 E:650 ||| -RRB-
.  ||| S:650 E:652 ||| .
All  ||| S:652 E:656 ||| DT
strains  ||| S:656 E:664 ||| NNS
were  ||| S:664 E:669 ||| VBD
treated  ||| S:669 E:677 ||| VBN
with  ||| S:677 E:682 ||| IN
different  ||| S:682 E:692 ||| JJ
concentrations  ||| S:692 E:707 ||| NNS
of  ||| S:707 E:710 ||| IN
norspermidine ||| S:710 E:723 ||| NN
,  ||| S:723 E:725 ||| ,
spermidine ||| S:725 E:735 ||| NN
,  ||| S:735 E:737 ||| ,
putrescine ||| S:737 E:747 ||| NN
,  ||| S:747 E:749 ||| ,
and  ||| S:749 E:753 ||| CC
cadaverine  ||| S:753 E:764 ||| NNS
( ||| S:764 E:765 ||| -LRB-
1 ||| S:765 E:766 ||| CD
,  ||| S:766 E:768 ||| ,
10 ||| S:768 E:770 ||| CD
,  ||| S:770 E:772 ||| ,
25 ||| S:772 E:774 ||| CD
,  ||| S:774 E:776 ||| ,
50  ||| S:776 E:779 ||| CD
and  ||| S:779 E:783 ||| CC
100 μM ||| S:783 E:789 ||| CD
) ||| S:789 E:790 ||| -RRB-
,  ||| S:790 E:792 ||| ,
and  ||| S:792 E:796 ||| CC
the  ||| S:796 E:800 ||| DT
biofilm  ||| S:800 E:808 ||| JJ
formation  ||| S:808 E:818 ||| NN
was  ||| S:818 E:822 ||| VBD
tested  ||| S:822 E:829 ||| VBN
on  ||| S:829 E:832 ||| IN
microtiter  ||| S:832 E:843 ||| JJ
plate ||| S:843 E:848 ||| NN
.  ||| S:848 E:850 ||| .
Besides ||| S:850 E:857 ||| RB
,  ||| S:857 E:859 ||| ,
cell-free  ||| S:859 E:869 ||| JJ
supernatants  ||| S:869 E:882 ||| NN
of  ||| S:882 E:885 ||| IN
S. epidermidis  ||| S:885 E:900 ||| CD
growth  ||| S:900 E:907 ||| NN
at  ||| S:907 E:910 ||| IN
4 h  ||| S:910 E:914 ||| NNP
and  ||| S:914 E:918 ||| CC
40 h  ||| S:918 E:923 ||| NNP
were  ||| S:923 E:928 ||| VBD
analyzed  ||| S:928 E:937 ||| VBN
by  ||| S:937 E:940 ||| IN
gas  ||| S:940 E:944 ||| NN
chromatography  ||| S:944 E:959 ||| VBZ
coupled  ||| S:959 E:967 ||| VBN
to  ||| S:967 E:970 ||| TO
mass  ||| S:970 E:975 ||| JJ
spectrometry  ||| S:975 E:988 ||| NNS
( ||| S:988 E:989 ||| -LRB-
GC-MS ||| S:989 E:994 ||| NNP
)  ||| S:994 E:996 ||| -RRB-
to  ||| S:996 E:999 ||| TO
detect  ||| S:999 E:1006 ||| VB
norspermidine ||| S:1006 E:1019 ||| NNS
.  ||| S:1019 E:1021 ||| .
Results  ||| S:1021 E:1029 ||| NNS
showed  ||| S:1029 E:1036 ||| VBD
that  ||| S:1036 E:1041 ||| DT
norspermidine  ||| S:1041 E:1055 ||| NN
at  ||| S:1055 E:1058 ||| IN
25 μM  ||| S:1058 E:1064 ||| NNP
and  ||| S:1064 E:1068 ||| CC
100 μM  ||| S:1068 E:1075 ||| NNP
prevented  ||| S:1075 E:1085 ||| VBD
the  ||| S:1085 E:1089 ||| DT
biofilm  ||| S:1089 E:1097 ||| JJ
formation  ||| S:1097 E:1107 ||| NN
in  ||| S:1107 E:1110 ||| IN
45.16 ||| S:1110 E:1115 ||| CD
%  ||| S:1115 E:1117 ||| NN
( ||| S:1117 E:1118 ||| -LRB-
14 ||| S:1118 E:1120 ||| CD
/ ||| S:1120 E:1121 ||| CD
31 ||| S:1121 E:1123 ||| CD
)  ||| S:1123 E:1125 ||| -RRB-
and  ||| S:1125 E:1129 ||| CC
16.13 ||| S:1129 E:1134 ||| CD
%  ||| S:1134 E:1136 ||| NN
( ||| S:1136 E:1137 ||| -LRB-
5 ||| S:1137 E:1138 ||| CD
/ ||| S:1138 E:1139 ||| CD
31 ||| S:1139 E:1141 ||| CD
) ||| S:1141 E:1142 ||| -RRB-
,  ||| S:1142 E:1144 ||| ,
respectively ||| S:1144 E:1156 ||| RB
;  ||| S:1156 E:1158 ||| :
only  ||| S:1158 E:1163 ||| RB
in  ||| S:1163 E:1166 ||| IN
one  ||| S:1166 E:1170 ||| CD
isolate  ||| S:1170 E:1178 ||| NN
from  ||| S:1178 E:1183 ||| IN
OI ||| S:1183 E:1185 ||| NNP
,  ||| S:1185 E:1187 ||| ,
norspermidine  ||| S:1187 E:1201 ||| NN
did  ||| S:1201 E:1205 ||| VBD
not  ||| S:1205 E:1209 ||| RB
have  ||| S:1209 E:1214 ||| VB
effect ||| S:1214 E:1220 ||| NN
.  ||| S:1220 E:1222 ||| .
Other  ||| S:1222 E:1228 ||| JJ
polyamines  ||| S:1228 E:1239 ||| NN
as  ||| S:1239 E:1242 ||| IN
spermidine ||| S:1242 E:1252 ||| NN
,  ||| S:1252 E:1254 ||| ,
putrescine  ||| S:1254 E:1265 ||| NN
and  ||| S:1265 E:1269 ||| CC
cadaverine  ||| S:1269 E:1280 ||| NNS
did  ||| S:1280 E:1284 ||| VBD
not  ||| S:1284 E:1288 ||| RB
have  ||| S:1288 E:1293 ||| VB
effect  ||| S:1293 E:1300 ||| NN
on  ||| S:1300 E:1303 ||| IN
the  ||| S:1303 E:1307 ||| DT
biofilm  ||| S:1307 E:1315 ||| JJ
formation  ||| S:1315 E:1325 ||| NN
of  ||| S:1325 E:1328 ||| IN
the  ||| S:1328 E:1332 ||| DT
strains  ||| S:1332 E:1340 ||| NNS
tested ||| S:1340 E:1346 ||| VBD
.  ||| S:1346 E:1348 ||| .
Norspermidine  ||| S:1348 E:1362 ||| NNP
was  ||| S:1362 E:1366 ||| VBD
also  ||| S:1366 E:1371 ||| RB
capable  ||| S:1371 E:1379 ||| JJ
to  ||| S:1379 E:1382 ||| TO
disassemble  ||| S:1382 E:1394 ||| VB
a  ||| S:1394 E:1396 ||| DT
biofilm  ||| S:1396 E:1404 ||| NN
already  ||| S:1404 E:1412 ||| RB
formed ||| S:1412 E:1418 ||| VBN
.  ||| S:1418 E:1420 ||| .
Norspermidine  ||| S:1420 E:1434 ||| NNP
was  ||| S:1434 E:1438 ||| VBD
detected  ||| S:1438 E:1447 ||| VBN
in  ||| S:1447 E:1450 ||| IN
the  ||| S:1450 E:1454 ||| DT
40 h  ||| S:1454 E:1459 ||| JJ
cell-free  ||| S:1459 E:1469 ||| JJ
supernatant  ||| S:1469 E:1481 ||| NN
of  ||| S:1481 E:1484 ||| IN
S. epidermidis  ||| S:1484 E:1499 ||| CD
by  ||| S:1499 E:1502 ||| IN
GC-MS ||| S:1502 E:1507 ||| JJ
.  ||| S:1507 E:1509 ||| .
Norspermidine  ||| S:1509 E:1523 ||| NNP
inhibited  ||| S:1523 E:1533 ||| VBD
the  ||| S:1533 E:1537 ||| DT
biofilm  ||| S:1537 E:1545 ||| JJ
development  ||| S:1545 E:1557 ||| NN
of  ||| S:1557 E:1560 ||| IN
S. epidermidis  ||| S:1560 E:1575 ||| CD
on  ||| S:1575 E:1578 ||| IN
the  ||| S:1578 E:1582 ||| DT
surface  ||| S:1582 E:1590 ||| NN
of  ||| S:1590 E:1593 ||| IN
contact  ||| S:1593 E:1601 ||| NN
lens ||| S:1601 E:1605 ||| NN
.  ||| S:1605 E:1607 ||| .
In  ||| S:1607 E:1610 ||| IN
this  ||| S:1610 E:1615 ||| DT
work ||| S:1615 E:1619 ||| NN
,  ||| S:1619 E:1621 ||| ,
it  ||| S:1621 E:1624 ||| PRP
was  ||| S:1624 E:1628 ||| VBD
demonstrated  ||| S:1628 E:1641 ||| VBN
that  ||| S:1641 E:1646 ||| IN
S. epidermidis  ||| S:1646 E:1661 ||| NNP
produces  ||| S:1661 E:1670 ||| VBZ
and  ||| S:1670 E:1674 ||| CC
releases  ||| S:1674 E:1683 ||| NNS
norspermidine  ||| S:1683 E:1697 ||| VBP
causing  ||| S:1697 E:1705 ||| VBG
an  ||| S:1705 E:1708 ||| DT
inhibitory  ||| S:1708 E:1719 ||| JJ
effect  ||| S:1719 E:1726 ||| NN
on  ||| S:1726 E:1729 ||| IN
biofilm  ||| S:1729 E:1737 ||| JJ
formation ||| S:1737 E:1746 ||| NN
.  ||| S:1746 E:1748 ||| .
Moreover ||| S:1748 E:1756 ||| RB
,  ||| S:1756 E:1758 ||| ,
this  ||| S:1758 E:1763 ||| DT
is  ||| S:1763 E:1766 ||| VBZ
the  ||| S:1766 E:1770 ||| DT
first  ||| S:1770 E:1776 ||| JJ
time  ||| S:1776 E:1781 ||| NN
showing  ||| S:1781 E:1789 ||| VBG
that  ||| S:1789 E:1794 ||| IN
clinical  ||| S:1794 E:1803 ||| JJ
S. epidermidis  ||| S:1803 E:1818 ||| CD
strains  ||| S:1818 E:1826 ||| NNS
have  ||| S:1826 E:1831 ||| VBP
different  ||| S:1831 E:1841 ||| JJ
sensitivity  ||| S:1841 E:1853 ||| NN
to  ||| S:1853 E:1856 ||| TO
norspermidine ||| S:1856 E:1869 ||| VB
,  ||| S:1869 E:1871 ||| ,
which  ||| S:1871 E:1877 ||| WDT
suggest  ||| S:1877 E:1885 ||| VBP
that  ||| S:1885 E:1890 ||| IN
the  ||| S:1890 E:1894 ||| DT
composition  ||| S:1894 E:1906 ||| NN
and  ||| S:1906 E:1910 ||| CC
structure  ||| S:1910 E:1920 ||| NN
of  ||| S:1920 E:1923 ||| IN
the  ||| S:1923 E:1927 ||| DT
biofilms  ||| S:1927 E:1936 ||| NN
is  ||| S:1936 E:1939 ||| VBZ
varied ||| S:1939 E:1945 ||| VBN
.  ||| S:1945 E:1947 ||| .
We  ||| S:1947 E:1950 ||| PRP
propose  ||| S:1950 E:1958 ||| VBP
that  ||| S:1958 E:1963 ||| DT
norspermidine  ||| S:1963 E:1977 ||| NN
could  ||| S:1977 E:1983 ||| MD
potentially  ||| S:1983 E:1995 ||| RB
be  ||| S:1995 E:1998 ||| VB
used  ||| S:1998 E:2003 ||| VBN
in  ||| S:2003 E:2006 ||| IN
the  ||| S:2006 E:2010 ||| DT
pre-treating  ||| S:2010 E:2023 ||| JJ
of  ||| S:2023 E:2026 ||| IN
medical  ||| S:2026 E:2034 ||| JJ
and  ||| S:2034 E:2038 ||| CC
surgical  ||| S:2038 E:2047 ||| JJ
devices  ||| S:2047 E:2055 ||| NNS
to  ||| S:2055 E:2058 ||| TO
inhibit  ||| S:2058 E:2066 ||| VB
the  ||| S:2066 E:2070 ||| DT
biofilm  ||| S:2070 E:2078 ||| JJ
formation ||| S:2078 E:2087 ||| NN
.  ||| S:2087 E:2089 ||| .
